José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Clinico Universitario de Valencia (46)
2024
-
Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia
Frontiers in Oncology, Vol. 14
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
Leukemia
2023
-
Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia
HemaSphere, Vol. 7, Núm. 8, pp. E936
-
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study
Journal of medical virology, Vol. 95, Núm. 7, pp. e28933
-
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors
British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61
-
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain
Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
Expert Review of Hematology, Vol. 15, Núm. 6, pp. 477-484
-
Breakthrough infections in MPN-COVID vaccinated patients
Blood Cancer Journal
-
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19
American Journal of Hematology
-
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
-
Second versus first wave of COVID-19 in patients with MPN
Leukemia
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
American Journal of Hematology, Vol. 96, Núm. 10, pp. 1186-1194